<DOC>
	<DOCNO>NCT02483104</DOCNO>
	<brief_summary>This Phase 1 , open-label , multicenter , dose escalation study evaluate tolerability , safety , pharmacokinetics preliminary efficacy veliparib combination carboplatin weekly paclitaxel Japanese subject ovarian cancer .</brief_summary>
	<brief_title>Veliparib Combination With Carboplatin And Weekly Paclitaxel Japanese Subjects With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm epithelial ovarian , fallopian tube primary peritoneal carcinoma International Federation Gynecology Obstetrics ( FIGO ) Stage IC IV either optimal ( &lt; 1 cm residual disease ) suboptimal residual disease . Participants must newly diagnose , chemotherapyna√Øve , enter 1 12 week initial cytoreductive surgery . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate organ marrow function . Ability swallow retain oral medication , uncontrolled emesis . Women childbearing potential ( except vasectomize partner female subject ) must agree use adequate contraception prior study entry , duration study participation 3 month follow completion therapy . Women childbearing potential must negative urine serum pregnancy test within 7 day prior study entry . Post menopausal woman must amenorrheic least 12 month consider nonchildbearing potential . A history another invasive cancer within past 3 year , except nonmelanoma skin cancer situ malignancy consider cured investigator ( e.g. , cervical cancer situ , situ carcinoma bladder , breast carcinoma situ ) . Participants receive prior radiotherapy portion abdominal cavity pelvis . Participants receive prior chemotherapy abdominal pelvic tumor . Any investigational agent le 4 week prior study enrollment . Any anticancer Chinese medicine/herbal remedy within 14 day prior study enrollment . Known history allergic reaction Cremophorpaclitaxel , carboplatin , Azo Colourant Tartrazine ( also know FD &amp; C Yellow 5 E102 ) , Azo Colourant Orange YellowS ( also know FD &amp; C Yellow 6 E110 ) know contraindication study supply drug . Patients history evidence upon physical examination central nervous system disease , include primary brain tumor , brain metastasis , history cerebrovascular accident ( CVA , stroke ) , transient ischemic attack ( TIA ) within 6 month first date treatment study . Prior therapy Poly ( ADPribose ) Polymerase ( PARP ) inhibitor . Subject clinically significant uncontrolled condition ( ) , include limited : Uncontrolled seizure disorder , focal generalized seizure within last 12 month ; Active infection require parenteral antibiotic ; Known active hepatitis B hepatitis C abnormal liver function test organ dysfunction ; Symptomatic congestive heart failure ; unstable angina pectoris ; serious ventricular cardiac arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation ) serious cardiac arrhythmia require medication ( include asymptomatic atrial fibrillation control ventricular rate ) ; myocardial infarction within last 6 month ; Uncontrolled hypertension ( sustain systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 100 mmHg despite optimal medical management ) ; Bowel obstruction gastric outlet obstruction ; Psychiatric illness/social situation would limit compliance study requirement ; Any medical condition opinion Investigator place subject unacceptably high risk toxicity . Pregnant lactating .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ABT-888</keyword>
	<keyword>BRCA</keyword>
	<keyword>Primary peritoneal cancer</keyword>
	<keyword>carboplatin</keyword>
	<keyword>Fallopian tube</keyword>
	<keyword>Poly ( ADP-ribose ) polymerase ( PARP )</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>veliparib</keyword>
</DOC>